文章预览
SCI 16 December 2024 Adjuvant Immunotherapy Does Not Improve Survival in Non-small Cell Lung Cancer with Major/Complete Pathological Response after Induction Immunotherapy (The journal of thoracic and cardiovascular surgery; if=4.9) Zhao ZR, Yan WP, Yu XY, Zhang JB, Fang YF, Ma K, Luo QQ, Long H, Chen KN, Jiang L. Correspondence: ianglong@shchest.org Objective 目的 In patients with resectable non-small cell lung cancer (NSCLC), immune checkpoint inhibitor (ICI)-based regimens in both neoadjuvant and perioperative settings demonstrate survival benefit. To date, no study has compared the efficacy between pure neoadjuvant and perioperative approaches, especially in patients who achieve substantial pathological responses. 在可切除的癌症（NSCLC）患者中，基于免疫检查点抑制剂（ICI）的方案在新辅助和围手术期均显示出生存益处。迄今为止，还没有研究比较纯新辅助和围手术期方法之间的疗效，特别是在获得实质性病理
………………………………
